Gelonghui May 12 丨 Baicheng Pharmaceutical (301096mfk200ml.SZ) announced that Zhejiang Thermo Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received a clinical trial approval notice from the State Food and Drug Administration (NMPA), and the company independently developed it.mfk200mlClinical trial studies will be carried out on the BIOS2207 drug. BIOS2207 is indicated for adults and children 4 years old and older with partial seizures (with or without secondary generalized seizures)mfk200mltreatment.